This GSK press release announces the completion of its acquisition of Nuvalent, a Boston-based clinical-stage biopharmaceutical firm, in a deal valued at roughly $10.6 billion in equity (about $9.4 billion net after cash acquired). The transaction brings GSK a portfolio of precision lung cancer therapies, led by two late-stage candidates, zidesamtinib and neladalkib, which target ROS1-positive and ALK-altered non-small cell lung cancer and carry FDA Breakthrough Therapy and Orphan Drug designations. An earlier-stage candidate, NVL-330 for HER2-altered NSCLC, is also included. GSK frames the purchase as a way to accelerate its move into lung cancer and broaden its oncology reach beyond blood and women's cancers, with anticipated near-term launches. For directory users, it signals GSK's expanding oncology pipeline and its appetite for acquiring specialized clinical assets.
This news post announces that Labtec, the Langenfeld-based research and development arm now part of the AdhexPharma group, is building a new toxicology laboratory. The facility adds cleanroom capacity suited to handling highly potent compounds and new chemical entities, extending Labtec's formulation-development and clinical-sample production services. The investment is aimed at supporting early-stage projects that require careful containment and controlled handling of potent actives. It reinforces the group's positioning in transdermal and oral-film drug delivery development. For directory users, it signals growing specialist capacity for potent-compound formulation work within a single integrated development partner. (Note: the former Tesa Labtec has been rebranded to Labtec and now sits under AdhexPharma, so its content lives on the adhexpharma.com domain.)
This Altasciences blog post examines AI hallucination, the tendency of language models to produce convincing but inaccurate or unsupported outputs, and why this poses particular risks in clinical research where data integrity and regulatory compliance are essential. It lays out five practical strategies to reduce such errors: prompting step-by-step chain-of-thought reasoning, leveraging reinforcement learning from human feedback so models better align with intended answers, and writing clear, constrained prompts that limit room for unfounded assumptions. The remaining strategies involve generating multiple independent reasoning paths and selecting the most consistent result, and offloading numerical work to external computational tools rather than relying on text-based estimates, which is especially useful for tasks like pharmacokinetic calculations. The author stresses that AI should serve as decision support rather than a final authority, with expert human review remaining indispensable. Verification of AI outputs against source data and regulatory guidance is presented as a core safeguard. For a pharmaceutical services directory, the article offers useful perspective on responsibly integrating AI into drug development workflows.
This Broughton blog post provides an overview of the current nitrosamines testing landscape and what pharmaceutical manufacturers should understand about it. It explains that nitrosamines form when nitrosating agents react with amines and that many are potent potential carcinogens, tracing how the issue moved from food safety concerns to a major pharmaceutical priority after NDMA was found in valsartan in 2018. The article summarizes the resulting regulatory expectations from bodies such as the MHRA, EMA, and FDA, which require lifecycle risk assessments and strict acceptable intake limits. It describes the multi-stage detection strategies needed, including risk assessment combined with sensitive, validated analytical methods like LC-MS and GC-MS, and stresses that risk can arise from raw materials, solvents, processing, and storage. Broughton positions itself as a specialist partner offering integrated testing, toxicology, and regulatory support. For directory users, it demonstrates a testing provider's expertise in an area of significant ongoing regulatory scrutiny.
This 3PBIOVIAN article examines the European contract development and manufacturing (CDMO/CMO) model and its role in advancing biologics innovation. It argues that Europe has emerged as a leading center for biologics thanks to its combination of scientific expertise, regulatory knowledge, and advanced manufacturing infrastructure. The piece frames the choice of manufacturing partner as a strategic decision that shapes program outcomes, stressing that early choices around scalability, quality standards, and regulatory alignment influence a therapy's long-term viability. It positions 3PBIOVIAN's pan-European footprint, broad technological expertise, and integrated end-to-end services as advantages that help clients accelerate development while reducing complexity across the product lifecycle. For those browsing a pharmaceutical services directory, the article is relevant as an overview of outsourced biologics manufacturing and CDMO partner selection in Europe.
If you feel you would like to publish a blog please contact us and we can add this to your application on your dashboard.
Should you have any questions or require further information please contact us ...
Contact the support team »
Check if your company is listed and claim your online profile ...
Search for your company listing »
If you're not listed in the directory and you want to build a public profile, register for an account ...
Register for an account to build a profile »
Apply for a live demo of our Partner Search and Software ...
Register your interest here and we will contact you within 24 hours»
